CLRB stock has been on a tear for the better part of the early hours of trading in Wednesday’s session after Cellectar Biosciences Inc (NASDAQ:CLRB) announced major positive news related to one of its flagship drugs.
The drug in question is CLR131 and once the initial results of the phase 1 trial for the drug showed positive results, CLRB stock price started going up. The dose that has been decided on for the drug in question proved to be effective enough according to the Independent Data Monitoring Committee and now the company is looking to raise ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.